The phase 2 trial aimed to investigate the efficacy and safety of surufatinib combined with sintilimab as a potential 1L treatment for patients with advanced GC/GEJC. The primary endpoint was to determine ORR. Researchers noticed promising preliminary efficacy and manageable safety of surufatinib plus sintilimab as 2L treatment for advanced GC/GEJC patients; further […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background Natural killer (NK) cell therapy is considered an attractive and safe strategy for anticancer therapy. Nevertheless, when autologous or allogenic NK cells are used alone, the clinical benefit has been disappointing. This is partially due …
Background Lenvatinib plus PD-1 inhibitors and interventional (LPI) therapy have demonstrated promising treatment effects in unresectable hepatocellular carcinoma (HCC). However, biomarkers for predicting the response to LPI therapy remain to be further explored. We aimed to …
Background Triple-negative breast cancer (TNBC) poses unique challenges due to its complex nature and the need for more effective treatments. Recent studies showed encouraging outcomes from combining paclitaxel (PTX) with programmed cell death protein-1 (PD-1) blockade …
Background Cervical cancer’s lymphatic spread primarily begins from the sentinel lymph nodes (SLNs), underlining their pivotal role in disease metastasis. However, these nodes’ immune gene expression profiles and immunoregulation mechanisms have yet to be explored. Methods Our study …
